Unused Drug Sample Clauses

Unused Drug. If the Study is terminated, suspended, discontinued, or completed, Institution or Investigator shall return to Idorsia or its designee any unused quanti- ties of the Study Drug, or upon Idorsia's re- quest, properly dispose of unused quanti- ties, in each case in accordance with Idorsia's instructions and together with a written certification thereof, at Idorsia's reasonable expense. Hodnocený přípravek výhradně pro účely provádění Klinického hodnocení a v souladu s Protokolem; (iv) omezí pří- xxxx k Hodnocenému přípravku pouze na ty Pracovníky podílející se na klinic- kém hodnocení, kteří jsou pod přímou kontrolou Zkoušejícího; (v) nevydávají Subjektům exspirované Hodnocený pří- pravek; a (vi) bez předchozího písem- ného souhlasu společnosti Idorsia ne- předávají žádné třetí osobě Hodnocený přípravek ani žádnou jeho část. 1.7.2 Služby lékárny: Zdravotnické zařízení zajistí, aby nemocniční lékárna (“Lé- kárna”) poskytovala služby požadované Zdravotnickým zařízením a/nebo Zkou- šejícím v souladu s Protokolem (“Služby lékárny”). Služby Lékárny zahrnují: (po- pis služby lékárny): příjem léčiva, kon- trolu uchování léčiva, výdej léčiva. 1.7.3
Sample 1
AutoNDA by SimpleDocs
Unused Drug. If the Study is terminated, suspended, discontinued, or completed, Institution or Investigator shall return to Idorsia or its designee any unused quantities of the Study Drug, , and Idorsia's instructions and together with a written certification thereof, at Idorsia's reasonable expense. 1.7.3
Sample 1
Unused Drug. If the Study is terminated, suspended, discontinued, or completed, Provider shall return to Actelion or its designee any unused quantities of the Study Drug, or upon Actelion´s request, properly dispose of unused quantities, in each case in accordance with Actelion´s instructions and together with a written certification thereof, at Actelion´s reasonable expense. 1.6.3
Sample 1
Unused Drug. If the Study is terminated, suspended, discontinued, or completed, Actelion agrees to take back unused packages of the Study Drugs at its own expense. The pharmacy does not provide destruction of the Study Drug and related administrative tasks. 1.7.4
Sample 1
Unused Drug. If the Study is terminated, suspended, discontinued, or completed, Institution or Investigator shall return to Idorsia or its designee any unused quantities of the Study Drug, or upon Idorsia's request, properly dispose of unused quantities, in each case in accordance with Idorsia's instructions and together with a written certification thereof, at Idorsia's reasonable expense. (“Lékárna”) poskytovala služby požadované Zdravotnickým zařízením a/nebo Zkoušejícím v souladu s Protokolem (“Služby lékárny”). Služby
Sample 1
Unused Drug. If the Study is terminated, suspended, discontinued, or completed, Institution or Investigator shall return to Idorsia or its designee any unused quantities of the Study Drug. hodnocení xx xxxxxxxx xxxxxxxxx xxxxxxxxx xx kontrolu zacházení s hodnoceným léčivým přípravkem podle zásad správné lékárenské praxe a pokynů zadavatele včetně vedení příslušné dokumentace. 3) Zadavatel se zavazuje uhradit služby pověřeného farmaceuta dle platného Ceníku služeb lékáren FN Plzeň pro klinická hodnocení léčivých přípravků na základě průkazné evidence jednotlivých provedených úkonů, vedené pověřeným farmaceutem. Rozsah požadovaných služeb definuje zadavatel prostřednictvím Dotazníku FN Plzeň .Platby za služby lékárny musí být odděleny od ostatních plateb ve studii. 4) Zadavatel se zavazuje po ukončení klinického hodnocení odebrat všechna spotřebovaná I nespotřebovaná balení hodnocených léčivých přípravků na vlastní náklady zpět. Lékárna nezajišťuje likvidaci těchto léčiv ani administrativu s ní související. 5) Zadavatel je povinen zajistit splnění výše uvedených podmínek i v případě, že komunikací s pověřeným farmaceutem nebo prováděním části úkonů v rámci klinického hodnocení (dodávky, monitoring atd.) pověří jiný subjekt. Za účelem snížení organizačních a zdravotních xxxxx xx zadavatel povinen každý takový subjekt o konkrétních dohodnutých podmínkách informovat. 1.7.2
Sample 1
Unused Drug. If the Study is terminated, suspended, discontinued, or completed, Institution or Investigator shall return to Idorsia or its designee any unused quantities of the Study Drug, or upon Idorsia's request, properly dispose of unused quantities, in each case in accordance with Idorsia's instructions and together with a written certification thereof, at Idorsia's reasonable expense. přímou kontrolou Zkoušejícího; (v) nevydávají Subjektům exspirované Hodnocený přípravek; a (vi) bez předchozího písemného souhlasu společnosti Idorsia nepředávají žádné třetí osobě Hodnocený přípravek ani žádnou jeho část. 1.7.2 Služby lékárny: Zdravotnické zařízení zajistí, aby nemocniční lékárna (“Lékárna”) poskytovala služby požadované Zdravotnickým zařízením a/nebo Zkoušejícím v souladu s Protokolem (“Služby lékárny”). Služby Lékárny zahrnují: příjem a výdej léčiva 1.7.3
Sample 1
AutoNDA by SimpleDocs

Related to Unused Drug

  • Unused Sick Leave The accrual of unused sick leave hours is unlimited. The City and the Union commit to the evaluation and establishment of a mutually beneficial non-use of sick leave incentive and pay-out policy. Until such time that a policy is established, accumulated sick leave shall be compensated as follows: Upon retirement from the City service, an employee shall be paid sixty percent (60%) of his accumulated sick leave, with the rate of payment based upon his regular pay at the time he retires. Upon the death of an employee, his beneficiary shall be paid sixty percent (60%) of his accumulated unused sick leave, with the payment based upon his regular pay at the date of his death.

  • Commitment Fees (i) On each Advance Date the Company shall pay to the Investor, directly from the gross proceeds held in escrow, an amount equal to five percent (5%) of the amount of each Advance. The Company hereby agrees that if such payment, as is described above, is not made by the Company on the Advance Date, such payment will be made at the direction of the Investor as outlined and mandated by Section 2.3 of this Agreement.

  • Facility Fee The Company shall pay to the Administrative Agent for the account of each Lender in accordance with its Applicable Percentage, a facility fee, in Dollars, equal to the Applicable Rate for facility fees times the actual daily amount of the Aggregate Commitments (or, if the Aggregate Commitments have terminated, on the Outstanding Amount of all Committed Loans, Swing Line Loans and L/C Obligations), regardless of usage, subject to adjustment as provided in Section 2.18. The facility fee shall accrue at all times during the Availability Period (and thereafter so long as any Committed Loans, Swing Line Loans or L/C Obligations remain outstanding), including at any time during which one or more of the conditions in Article IV are not met, and shall be due and payable quarterly in arrears on the last Business Day of each March, June, September and December, commencing with the first such date to occur after the Closing Date, and on the last day of the Availability Period (and, if applicable, thereafter on demand). The facility fee shall be calculated quarterly in arrears, and if there is any change in the Applicable Rate for facility fees during any quarter, the actual daily amount shall be computed and multiplied by the Applicable Rate for facility fees separately for each period during such quarter that such Applicable Rate for facility fees was in effect.

  • Daily Rate One, divided by the number of days in the teacher’s annual base contract, times his/her base salary.

  • Commitment Fee The Borrower shall pay to the Administrative Agent, for the account of each Lender in accordance with its Applicable Percentage, a commitment fee equal to the product of (i) the Applicable Rate times (ii) the actual daily amount by which the Aggregate Revolving Commitments exceed the sum of (y) the Outstanding Amount of Revolving Loans and (z) the Outstanding Amount of L/C Obligations, subject to adjustment as provided in Section 2.15. For the avoidance of doubt, the Outstanding Amount of Swing Line Loans shall not be counted towards or considered usage of the Aggregate Revolving Commitments for purposes of determining the commitment fee. The commitment fee shall accrue at all times during the Availability Period, including at any time during which one or more of the conditions in Article IV is not met, and shall be due and payable quarterly in arrears on the last Business Day of each March, June, September and December, commencing with the first such date to occur after the Closing Date, and on the last day of the Availability Period. The commitment fee shall be calculated quarterly in arrears, and if there is any change in the Applicable Rate during any quarter, the actual daily amount shall be computed and multiplied by the Applicable Rate separately for each period during such quarter that such Applicable Rate was in effect.

Time is Money Join Law Insider Premium to draft better contracts faster.